Lv5
1230 积分 2023-05-06 加入
Inhibitors and PROTACs of CDK2: challenges and opportunities
2天前
已完结
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
2天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
3天前
已完结
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
3天前
已完结
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
6天前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
6天前
已完结
Molecular Glue Discovery: Current and Future Approaches
22天前
已完结
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
23天前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
23天前
已完结
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
23天前
已完结
皖公网安备34019202002308
